戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ytic response to a cholinesterase inhibitor, aldicarb.
2 nimals to the acetylcholinesterase inhibitor aldicarb.
3 ere is an accelerated rate of contraction on aldicarb.
4 ffects of an acetylcholinesterase inhibitor, aldicarb.
5 bition of egg laying and fails to respond to aldicarb.
6 nimals to the acetylcholinesterase inhibitor aldicarb.
7 stance to the acetylcholinesterase inhibitor aldicarb.
8 chlorpyrifos, chlorfenviphos, parathion, and aldicarb.
9 gus using the acetylcholinesterase inhibitor aldicarb.
10 stem has been developed for the detection of aldicarb (ALD) based on inner filter effect (IFE) of gol
11 reased egg laying and were hypersensitive to aldicarb, an inhibitor of acetylcholinesterase, suggesti
12  Carbamate insecticide screens often include aldicarb and its oxidative metabolites, aldicarb sulfoxi
13 adult worms are incubated in the presence of aldicarb and scored for the time-course of aldicarb-indu
14 istant to the acetylcholinesterase inhibitor aldicarb, and they exhibit reduced swimming rates in liq
15                                Recoveries of aldicarb, ASX and ASN from excreta were of 79% +/- 5.4,
16                                        Since aldicarb, ASX, and ASN are normally detectable in organ
17  HPLC postcolumn derivitization to determine aldicarb, ASX, and ASN from avian excreta and from gastr
18  or no embryo toxicity (cyanazine, picloram, aldicarb, azinphos-methyl, dieldrin, diquat dibromide, e
19 sol, ethylacrylate, malathion, chlorpyrifos, aldicarb, carbofuran, carbaryl, 2,4-dichlorophenol, 2,4,
20 vity, with either mutations or the inhibitor aldicarb, decreased egg laying.
21 lly exhibit a change in their sensitivity to aldicarb (either increased sensitivity for enhancements
22 es an important forensic tool for evaluating aldicarb exposures.
23 se reducing their function results in strong aldicarb hypersensitivity and hyperactive locomotion.
24 istant to the acetylcholinesterase inhibitor aldicarb, indicating that cholinergic transmission is im
25 ghtened drug responsiveness was caused by an aldicarb-induced increase in muscle ACR-16 acetylcholine
26 ng the DVA mechanoreceptor (TRP-4) decreased aldicarb-induced NLP-12 secretion and blocked aldicarb-i
27 f aldicarb and scored for the time-course of aldicarb-induced paralysis.
28 with increased PKC-1 activity had more rapid aldicarb-induced paralysis.
29 ailure) and also with altered sensitivity to aldicarb-induced paralysis.
30                                              Aldicarb-induced potentiation was eliminated by mutation
31 ldicarb-induced NLP-12 secretion and blocked aldicarb-induced synaptic potentiation.
32  treatment with the cholinesterase inhibitor aldicarb induces a form of presynaptic potentiation wher
33 e rate of animal contraction when exposed to aldicarb is controlled by the balance between excitatory
34 les are primary transformation products from aldicarb, its sulfoxide, or its sulfone.
35                                              Aldicarb nitrile, ASX nitrile, and ASN nitrile recoverie
36 key determinants of the inhibitory effect of aldicarb on pharyngeal pumping are located at the body w
37 f the effect of the cholinesterase inhibitor aldicarb on the rate of pharyngeal pumping on food in mu
38 ic drugs such as ivermectin, levamisole, and aldicarb, representing a potential route for targeting p
39 se reducing their function results in strong aldicarb resistance and slow locomotion rates.
40 G(q)alpha signaling network by screening for aldicarb-resistant mutants with phenotypes similar to eg
41             By contrast, genetic analysis of aldicarb responses and imaging of fluorescently tagged n
42 nalysis of a YFP-tagged NLP-12 suggests that aldicarb stimulates DVA secretion of NLP-12.
43 al assays using the cholinesterase inhibitor aldicarb suggest that VAs and GOA-1 similarly downregula
44 stance to the acetylcholinesterase inhibitor aldicarb, suggesting a defect in the neuronal presynapti
45 istant to the acetylcholinesterase inhibitor aldicarb, suggesting that cholinergic transmission was g
46 e metabolites, aldicarb sulfoxide (ASX), and aldicarb sulfone (ASN).
47 lude aldicarb and its oxidative metabolites, aldicarb sulfoxide (ASX), and aldicarb sulfone (ASN).
48 stance to the acetylcholinesterase inhibitor aldicarb, they are significantly hypersensitive to the a
49 tivity to an acetylcholinesterase inhibitor, aldicarb, uncovering deficiencies in inhibitory neurotra
50 nduced by the acetylcholinesterase inhibitor aldicarb, whereas mutants with increased PKC-1 activity